Article
Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure.
ESMO open - 1 Jul 2024
Huang R J, Huang Y S, An N, Hu J J, Wu C Y, Chen Y X, Chen J Y, Zhao Q, Xu R H, Yuan S Q, Wang F
Abstract excerpt
BACKGROUND: High tumor mutational burden (TMB) is one of the widely researched predictive biomarkers of immune checkpoint inhibitors and has been shown to be closely related with response to immunotherapy in multiple cancer types. However, for patients who have failed conventional therapy and are about to undergo immunotherapy, there is no consensus recommendation on the timing of tumor sampling for TMB analysis,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.